Loading...
EGFR-TKIs in adjuvant treatment of lung cancer: to give or not to give?
Epidermal growth factor receptor-tyrosine-kinase inhibitors (EGFR-TKIs) brought a significant revolution in the treatment of non-small-cell lung cancer (NSCLC). In a short period of time, EGFR-TKIs became the standard of treatment for mutation-positive, advanced stage non-squamous NSCLC. In recent y...
Na minha lista:
| Udgivet i: | Onco Targets Ther |
|---|---|
| Main Authors: | , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Dove Medical Press
2015
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4610780/ https://ncbi.nlm.nih.gov/pubmed/26508876 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S91627 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|